MS

Michael Selsted

Chief Scientific Officer at ORYN THERAPEUTICS, Inc.

No bio yet


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


ORYN THERAPEUTICS, Inc.

Oryn Therapeutics is a clinical-stage company developing a new class of drug candidates, Orynotides. These proprietary drug candidates are engineered, stable, cyclic peptides with very low immunogenicity and toxicity. They modulate pathologic inflammation and have proven effective in animal models of autoimmune and chronic inflammatory diseases such as rheumatoid arthritis and ulcerative colitis. They have proven effective in preclinical cancer models and augment natural host defense, functioning as host-directed anti-infectives against drug resistant pathogens.


Employees

11-50

Links